Liang Xiong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liang Xiong has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Juan Hua
Department of Cardiovascular Medicine The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University Nanchang Jiangxi P. R. China
5 shared publicationsDandan Wang
Department of Cardiovascular Medicine The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University Nanchang Jiangxi P. R. China
4 shared publications- Qi Chen
Department of Cardiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1 Minde Road, Nanchang, Jiangxi Province 330006, China
4 shared publications Chunwei Cheng
School of Medicine, Jiangxi University of Technology, Nanchang, China
1 shared publication- Dandan Wang
Department of Cardiology, the Second Affiliated Hospital of Nanchang University, Nanchang, China
1 shared publication - Hao Li
Second Affiliated Hospital of NanChang University
1 shared publication
Latest Publications
- 28 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Ventricular False Tendons and Ventricular Arrhythmias: Distinguishing Incidental Findings From Culprit Substrates
Ventricular false tendons are fibrous or fibromuscular cords that cross the ventricular cavity. Some contain Purkinje tissue and have been implicated in premature ventricular complexes, left posterior fascicular ventricular tachycardia, and, rarely, ventricular fibrillation. However, false tendons are also common in healthy hearts, so their visibility does not establish causality. This narrative review critically appraises the evidence and addresses three unresolved mechanistic questions. First, it is unclear whether a posteroseptal tendon forms the circuit of fascicular tachycardia or carries part of the adjacent Purkinje network. Control data are lacking, and ablation lesions involve both structures. Second, the slow, decremental, and verapamil‐sensitive conduction of the P1 pathway may reflect abnormal Purkinje tissue, reduced electrical coupling, or mixed tissue composition. Third, successful ablation sites cluster at tendon insertions. We propose a junctional hypothesis in which the insertion, where a thin Purkinje‐containing cord must depolarize a large myocardial mass, may form an arrhythmogenic interface. This model is untested but may account for insertion‐based targets, verapamil sensitivity, and exit shifts. We also propose a graded framework that classifies a tendon as an unlikely, possible, probable, or definite culprit. A definite grade requires concordant anatomical, electrical, imaging, and procedural evidence plus at least one observation that separates the tendon from adjacent tissue. By these criteria, most reported culprit tendons are probable rather than definite. A false tendon is best regarded as a visible segment of the Purkinje network whose arrhythmogenic potential may depend on how and where it couples to the myocardium.
- 28 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Ventricular False Tendons and Ventricular Arrhythmias: Distinguishing Incidental Findings From Culprit Substrates
Ventricular false tendons are fibrous or fibromuscular cords that cross the ventricular cavity. Some contain Purkinje tissue and have been implicated in premature ventricular complexes, left posterior fascicular ventricular tachycardia, and, rarely, ventricular fibrillation. However, false tendons are also common in healthy hearts, so their visibility does not establish causality. This narrative review critically appraises the evidence and addresses three unresolved mechanistic questions. First, it is unclear whether a posteroseptal tendon forms the circuit of fascicular tachycardia or carries part of the adjacent Purkinje network. Control data are lacking, and ablation lesions involve both structures. Second, the slow, decremental, and verapamil‐sensitive conduction of the P1 pathway may reflect abnormal Purkinje tissue, reduced electrical coupling, or mixed tissue composition. Third, successful ablation sites cluster at tendon insertions. We propose a junctional hypothesis in which the insertion, where a thin Purkinje‐containing cord must depolarize a large myocardial mass, may form an arrhythmogenic interface. This model is untested but may account for insertion‐based targets, verapamil sensitivity, and exit shifts. We also propose a graded framework that classifies a tendon as an unlikely, possible, probable, or definite culprit. A definite grade requires concordant anatomical, electrical, imaging, and procedural evidence plus at least one observation that separates the tendon from adjacent tissue. By these criteria, most reported culprit tendons are probable rather than definite. A false tendon is best regarded as a visible segment of the Purkinje network whose arrhythmogenic potential may depend on how and where it couples to the myocardium.
- 2 April 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 49 (10) , 1559-1562
Bipolar Radiofrequency Ablation of Atrial Tachycardia Originating From RAA via Pericardium Pathway‐A Case Report
Atrial tachycardia originating from the right atrial appendage was first reported more than a decade ago, which had been observed to occur more frequently in younger populations. Radiofrequency catheter ablation of this type of tachycardia often yielded suboptimal success rates, largely attributable to the complex anatomical structure of the right atrial appendage. In this report, we presented a successful case of bipolar radiofrequency ablation for atrial tachycardia arising from the right atrial appendage, which might offer a promising approach for the treatment of similar cases in the future.
- 2 April 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 49 (10) , 1559-1562
Bipolar Radiofrequency Ablation of Atrial Tachycardia Originating From RAA via Pericardium Pathway‐A Case Report
Atrial tachycardia originating from the right atrial appendage was first reported more than a decade ago, which had been observed to occur more frequently in younger populations. Radiofrequency catheter ablation of this type of tachycardia often yielded suboptimal success rates, largely attributable to the complex anatomical structure of the right atrial appendage. In this report, we presented a successful case of bipolar radiofrequency ablation for atrial tachycardia arising from the right atrial appendage, which might offer a promising approach for the treatment of similar cases in the future.
- Open Access
- 21 November 2024
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 29 (6) , e70034
Catheter Ablation of Ventricular Premature Contractions Originating From RVOT With Interruption of the Inferior Vena Cava—A Case Report
Ventricular premature contractions (VPC) originating from right ventricular outflow tract is the most common type of ventricular arrhythmias in clinic settings, which can be effectively cured by catheter ablation. Interruption of the inferior vena cava (IVC) is a rare vascular anomaly resulting from aberrant development during embryogenesis. Herein, we reported a very rare case of VPC originating from right ventricular outflow tract (RVOT) with interruption of IVC, which was successfully ablated by transfemoral vein approach.
- 21 November 2024
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 29 (6) , e70034
Open AccessCatheter Ablation of Ventricular Premature Contractions Originating From RVOT With Interruption of the Inferior Vena Cava—A Case Report
Ventricular premature contractions (VPC) originating from right ventricular outflow tract is the most common type of ventricular arrhythmias in clinic settings, which can be effectively cured by catheter ablation. Interruption of the inferior vena cava (IVC) is a rare vascular anomaly resulting from aberrant development during embryogenesis. Herein, we reported a very rare case of VPC originating from right ventricular outflow tract (RVOT) with interruption of IVC, which was successfully ablated by transfemoral vein approach.
- Open Access
- 11 November 2024
- Published by Wiley
Pulse field ablation of paroxysmal atrial fibrillation complicated with left-side accessory pathway—a Case report
We report a case of a patient with paroxysmal atrial fibrillation associated with left-side accessory pathway treated with pulsed field ablation. The patient successfully achieved long-term control of atrial fibrillation, which provides a new therapeutic option for clinical decision-making.
- 11 November 2024
- Published by Wiley
Open AccessPulse field ablation of paroxysmal atrial fibrillation complicated with left-side accessory pathway—a Case report
We report a case of a patient with paroxysmal atrial fibrillation associated with left-side accessory pathway treated with pulsed field ablation. The patient successfully achieved long-term control of atrial fibrillation, which provides a new therapeutic option for clinical decision-making.
- Open Access
- 9 July 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (5) , 1001-1010
Long-Term Stimulation of the Left Dorsal Branch of the Thoracic Nerve Improves Ventricular Electrical Remodeling in a Canine Model of Chronic Myocardial Infarction
Purpose: To evaluate the ventricular electrophysiologic effects of long-term stimulation of the left dorsal branch of thoracic nerve (LDTN) derived from the left stellate ganglion (LSG) in a canine model of chronic myocardial infarction (MI). Methods: Seventeen adult male beagles were randomly divided into three groups: the sham group (sham operated, n = 6), the MI group ( n = 6), and the MI + LDTN group (MI plus LDTN stimulation, n = 5). The canine model of chronic MI was induced by the occlusion of the left anterior descending artery (LADO). The LDTN was separated and intermittently stimulated immediately after LADO for 2 months. The heart rate variability (HRV) analysis, in vivo electrophysiology, the evaluation of LSG function and neural activity, histological staining, and western blotting (WB) assay were performed to evaluate the effect of LDTN stimulation on the heart. Results: The canine MI model was successfully established by LADO, and the LDTN was separated and stimulated immediately after LADO. The HRV analysis showed that LDTN stimulation reversed the increased LF value and LF/HF ratio of the MI group. LDTN stimulation prolonged the shortening ERP and APD90, decreased the dispersion of ERP and APD90, and increased the VFT. Additionally, LDTN stimulation inhibits the LSG function and neural activity. Furthermore, LDTN stimulation suppressed the activation of Wnt/β-catenin signaling, which contributed to the LSG neuronal apoptosis by upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-2. Conclusion: LDTN stimulation could attenuate cardiac sympathetic remodeling and improve ventricular electrical remodeling, which may be mediated by suppressing the activated Wnt/β-catenin signaling pathway and then promoting the LSG neuronal apoptosis.
- 9 July 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (5) , 1001-1010
Open AccessLong-Term Stimulation of the Left Dorsal Branch of the Thoracic Nerve Improves Ventricular Electrical Remodeling in a Canine Model of Chronic Myocardial Infarction
Purpose: To evaluate the ventricular electrophysiologic effects of long-term stimulation of the left dorsal branch of thoracic nerve (LDTN) derived from the left stellate ganglion (LSG) in a canine model of chronic myocardial infarction (MI). Methods: Seventeen adult male beagles were randomly divided into three groups: the sham group (sham operated, n = 6), the MI group ( n = 6), and the MI + LDTN group (MI plus LDTN stimulation, n = 5). The canine model of chronic MI was induced by the occlusion of the left anterior descending artery (LADO). The LDTN was separated and intermittently stimulated immediately after LADO for 2 months. The heart rate variability (HRV) analysis, in vivo electrophysiology, the evaluation of LSG function and neural activity, histological staining, and western blotting (WB) assay were performed to evaluate the effect of LDTN stimulation on the heart. Results: The canine MI model was successfully established by LADO, and the LDTN was separated and stimulated immediately after LADO. The HRV analysis showed that LDTN stimulation reversed the increased LF value and LF/HF ratio of the MI group. LDTN stimulation prolonged the shortening ERP and APD90, decreased the dispersion of ERP and APD90, and increased the VFT. Additionally, LDTN stimulation inhibits the LSG function and neural activity. Furthermore, LDTN stimulation suppressed the activation of Wnt/β-catenin signaling, which contributed to the LSG neuronal apoptosis by upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-2. Conclusion: LDTN stimulation could attenuate cardiac sympathetic remodeling and improve ventricular electrical remodeling, which may be mediated by suppressing the activated Wnt/β-catenin signaling pathway and then promoting the LSG neuronal apoptosis.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 30
Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Cirrhotic Patients: A Systematic Review and Meta-Analysis
Objective: Currently, there is limited evidence regarding the use of direct oral anticoagulants (DOACs) for patients with liver cirrhosis (LC). We performed a meta-analysis to compare the efficacy and safety of DOACs versus warfarin in this population. Methods: We searched PubMed, Cochrane Library, Web of Science, Embase and Scopus databases from inception to August 2024. Clinical studies comparing the use of DOACs with warfarin in cirrhotic patients were included. Hazard ratios (HRs) with 95% CIs were estimated by either fixed or random effects models. Primary efficacy outcomes were ischemic stroke/thromboembolism (IS/TE) and all-cause death, the primary safety outcomes were the bleeding risks. Results: Sixteen studies were included (16 829 individuals). DOACs had similar benefits in preventing IS/TE (HR = 0.87, 95% CI: 0.69-1.10), but DOACs were significantly associated with reduced risk of all-cause death (HR = 0.87, 95% CI: 0.79-0.97). On the other hand, we observed significantly reduced risks of any bleeding (HR = 0.60; 95%CI: 0.37-0.95), major bleeding (HR = 0.72; 95%CI: 0.63-0.82), intracranial hemorrhage (ICH) (HR = 0.47; 95%CI: 0.30-0.73), and gastrointestinal bleeding (GIB) (HR = 0.72, 95% CI: 0.60-0.87) in patients receiving DOACs. Results were consistent in cirrhotic patients with AF. Furthermore, DOACs reduced the incidence of major bleeding (HR = 0.65, 95%CI: 0.55-0.78) and ICH (HR = 0.17, 95%CI: 0.04-0.76) in patients with moderate to severe cirrhosis. Conclusion: Our study demonstrates that DOACs, compared with warfarin, exerted comparable efficacy and better safety and may represent a safer alternative to warfarin in cirrhotic patients.
- 1 January 2024
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 30
Open AccessComparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Cirrhotic Patients: A Systematic Review and Meta-Analysis
Objective: Currently, there is limited evidence regarding the use of direct oral anticoagulants (DOACs) for patients with liver cirrhosis (LC). We performed a meta-analysis to compare the efficacy and safety of DOACs versus warfarin in this population. Methods: We searched PubMed, Cochrane Library, Web of Science, Embase and Scopus databases from inception to August 2024. Clinical studies comparing the use of DOACs with warfarin in cirrhotic patients were included. Hazard ratios (HRs) with 95% CIs were estimated by either fixed or random effects models. Primary efficacy outcomes were ischemic stroke/thromboembolism (IS/TE) and all-cause death, the primary safety outcomes were the bleeding risks. Results: Sixteen studies were included (16 829 individuals). DOACs had similar benefits in preventing IS/TE (HR = 0.87, 95% CI: 0.69-1.10), but DOACs were significantly associated with reduced risk of all-cause death (HR = 0.87, 95% CI: 0.79-0.97). On the other hand, we observed significantly reduced risks of any bleeding (HR = 0.60; 95%CI: 0.37-0.95), major bleeding (HR = 0.72; 95%CI: 0.63-0.82), intracranial hemorrhage (ICH) (HR = 0.47; 95%CI: 0.30-0.73), and gastrointestinal bleeding (GIB) (HR = 0.72, 95% CI: 0.60-0.87) in patients receiving DOACs. Results were consistent in cirrhotic patients with AF. Furthermore, DOACs reduced the incidence of major bleeding (HR = 0.65, 95%CI: 0.55-0.78) and ICH (HR = 0.17, 95%CI: 0.04-0.76) in patients with moderate to severe cirrhosis. Conclusion: Our study demonstrates that DOACs, compared with warfarin, exerted comparable efficacy and better safety and may represent a safer alternative to warfarin in cirrhotic patients.